UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

 

November 12, 2008


AVOCENT CORPORATION

(Exact name of registrant as specified in its charter)


DELAWARE

000-30575

91-2032368

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


4991 CORPORATE DRIVE

 

HUNTSVILLE, AL 35805

(Address of principal executive offices)

  (Zip Code)


Registrant’s telephone number, including area code

 

(256) 430-4000


n/a

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 7.01     Regulation FD Disclosure.

On November 12, 2008, Avocent Corporation publicly disseminated a press release reaffirming guidance for the fourth quarter of 2008 as set forth in its press release dated October 21, 2008.  The Company expects to provide more detail at a presentation on November 12th in New York and in a live simulcast of the meeting on the Internet.  The information contained in that press release is incorporated herein by reference and furnished as Exhibit 99.22 hereto.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits.
 

Exhibit Number

Description of Exhibit

99.22

Press Release issued November 12, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AVOCENT CORPORATION

Date:

November 12, 2008

 

 

By:

/s/ Edward H. Blankenship

Edward H. Blankenship

Senior VP of Finance and Chief Financial Officer


EXHIBIT INDEX

Exhibit Number

 

Description of Exhibit

99.22

Press Release issued November 12, 2008